Innoviva Quarterly Income Statement
NASDAQ: INVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Innoviva revenue and earnings
In the quarter ended Jun 30, 2026, Innoviva generated $119.6 million in revenue, up 19.3% from the same quarter a year earlier. Innoviva reported a net loss of $83.4 million, compared with net income of $63.7 million a year earlier. Gross margin was 75.8% (down from 82.9%) and operating margin 42.5%.
Diluted earnings per share came in at -$1.14, down from $0.77.
Summary generated from market data by MetaCap's automated system. Methodology
Innoviva income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 119.59M | 97.99M | 114.61M | 107.80M | 100.28M | 88.63M | 91.81M | 89.51M | 99.90M | 77.50M | 85.84M | 67.26M |
| Revenue growth (YoY) | +19.25% | +10.56% | +24.84% | +20.44% | +0.39% | +14.37% | +6.95% | +33.08% | +23.34% | +1.48% | +30.45% | +0.00% |
| Gross Profit | 90.62M | 75.83M | 75.67M | 75.54M | 83.15M | 73.31M | 78.13M | 73.01M | 84.99M | 60.09M | — | — |
| Operating Expenses | 39.76M | 37.68M | 36.68M | 40.96M | 34.40M | 31.89M | 34.99M | 29.77M | 30.30M | 34.28M | — | — |
| Research & Development | 5.19M | 5.24M | 4.55M | 13.67M | 7.98M | 4.40M | 3.67M | 3.55M | 2.56M | 3.88M | 2.36M | 3.99M |
| Selling, General & Admin | 34.57M | 32.44M | 32.12M | 27.29M | 26.41M | 27.49M | 31.33M | 26.22M | 27.74M | 30.41M | 26.32M | 28.64M |
| Operating Income | 50.85M | 38.15M | 38.99M | 34.58M | 48.75M | 41.43M | 43.14M | 43.24M | 54.69M | 25.80M | — | — |
| Interest Expense | 5.47M | 5.44M | 3.31M | 4.01M | 4.66M | 4.71M | 4.75M | 5.81M | 5.80M | 5.85M | 5.95M | 4.40M |
| Other Income (Expense) | -15.00K | -366.00K | -612.00K | -479.00K | -777.00K | -996.00K | 126.00K | -914.00K | -973.00K | -1.24M | -680.00K | -1.05M |
| Pretax Income | -108.02M | 234.56M | 195.04M | 97.82M | 72.60M | -38.59M | 24.69M | 6.85M | -39.28M | 45.12M | 61.20M | 85.95M |
| Income Tax | -24.60M | 47.97M | 30.88M | 7.91M | 8.91M | 8.00M | 4.36M | 5.64M | -4.59M | 8.59M | -330.00K | 3.91M |
| Net Income | -83.42M | 186.59M | 164.15M | 89.91M | 63.69M | -46.58M | 20.33M | 1.21M | -34.69M | 36.53M | 61.53M | 82.05M |
| Net Income growth (YoY) | -230.98% | — | +707.36% | +7312.04% | — | -227.52% | -66.96% | -98.52% | -2809.77% | +4.78% | — | -64.23% |
| EPS (Basic) | -1.14 | 2.52 | 2.45 | 1.30 | 1.01 | -0.74 | 0.32 | 0.02 | -0.55 | 0.58 | 0.96 | 1.26 |
| EPS (Diluted) | -1.14 | 2.22 | 2.19 | 1.08 | 0.77 | -0.74 | 0.43 | 0.02 | -0.55 | 0.46 | 0.78 | 0.98 |
| Shares Outstanding (Basic) | 73.42M | 74.16M | — | 69.06M | 62.87M | 62.71M | — | 62.57M | 62.53M | 63.19M | — | 64.95M |
| Shares Outstanding (Diluted) | 73.42M | 84.85M | — | 84.96M | 84.45M | 62.71M | — | 62.95M | 62.53M | 84.53M | — | 86.16M |
| Gross Margin | 75.77% | 77.39% | 66.02% | 70.07% | 82.91% | 82.72% | 85.10% | 81.56% | 85.07% | 77.53% | — | — |
| Operating Margin | 42.52% | 38.94% | 34.02% | 32.08% | 48.61% | 46.74% | 46.99% | 48.31% | 54.74% | 33.30% | — | — |
| Net Margin | -69.75% | 190.41% | 143.22% | 83.40% | 63.51% | -52.56% | 22.15% | 136.00% | -34.72% | 47.14% | 71.68% | 121.99% |
This table shows 12 quarterly periods of Innoviva's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow INVA's reporting calendar. What is a income statement?